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ABSTRACT 
Introduction: Cardiovascular diseases (CVDs) are responsible of 31% of all deaths 
worldwide. Genetic predisposition to CVDs in adolescents remains largely unknown. 
Objective: To examine the association of UCP1, UCP2 and UCP3 gene 
polymorphisms with CVDs risk factors in European adolescents. 
Study design: A cross-sectional study that involves 1.057 European adolescents (12- 
18 years old) from the HELENA Study. A total of 18 polymorphisms of UCP1, 
UCP2 and UCP3 genes were genotyped. We measured serum total cholesterol, HDL, 
ApoA1, ApoB, leptin, triglycerides, glucose, insulin, blood pressure, and calculated 
HOMA (homeostatic model assessment) and a CVD Risk Score. 
Results: The G allele of UCP2 rs2735572 and T allele of UCP2 rs17132534 were 
associated with higher diastolic blood pressure (P=0.001; FDR=0.009 and P=8e−04; 
FDR=0.009, respectively). We observed that the AATAG haplotype of UCP1 was 
associated with higher serum ApoB/ApoA1 (P= 0.008; FDR = 0.031) and  ApoB 
levels (P= 0.008; FDR = 0.031). Moreover, the ACC haplotype of UCP3 was 
associated with a higher CVD risk score (P= 0.0036; FDR = 0.01). 
Conclusions: Two UCP2 polymorphisms and haplotypes of UCP1 and UCP3 were 
associated with CVD risk factors. These  findings  suggest that UCPs may have a role 
in the development of CVD already in adolescents. 
Introduction 
Cardiovascular diseases (CVDs) are the main cause of premature death and chronic 
disability worldwide (1). CVD events occur most frequently during or after the fifth 
decade of life, however, there is evidence indicating that the precursors of CVD have 
its origin in the first decades of life (2). Therefore, prevention is  fundamental  to 
reduce the incidence of these pathologies, especially in young people. 
CVDs are a result of complex harmful interactions between environmental and 
genetic risk factors. Environmental factors include unhealthy diet, tobacco use or 
physical inactivity (3). However, efforts have been insufficient to decrease the 
prevalence and new pathogenic dimensions come into play. Recent studies have 
described the association between some single nucleotide polymorphisms  (SNPs) 
with myocardial infarction (4) and other cardiovascular complications (5). For 
example, uncoupling protein genes (UCPs) have been associated with risk factors of 
cardiovascular disease such as prediabetes and type 2 diabetes mellitus (T2DM) (6), 
overweight and obesity (7,8), plasma levels of cholesterol (9) or hypertension (HT) 
(10) , mainly in adults over 50 years of age.
The most studied UCP genes are: i) UCP1, which main function is heat 
production through non-shivering thermogenesis  in brown adipose tissue (BAT) (11); 
ii) UCP2, in addition to may have a regulating role  in thermogenesis of BAT,  seems
to be involved in the control of reactive oxygen species (ROS) production (12,13), the 
modulation of insulin secretion (14) and the regulation of mitochondrial fatty acid 
oxidation (15), and iii) UCP3, which role has been related to  the coupling regulation 
of mitochondrial respiration in skeletal muscle mitochondria (16) and fatty acids 
oxidation (17), and is a mediator of thermogenesis (18). The playing role of 
uncoupling   proteins   in  human   physiology   makes    UCPs   ideal   targets  against 
cardiovascular-associated pathologies. Indeed, several SNPs of UCP2 (rs660339, 
rs659366) (19,20) and UCP3 (rs2075577, rs3781907, rs1800006, rs1800849) (19,21– 
23) have been associated with T2DM, overweight/obesity, serum total and LDL- 
cholesterol and others cardiovascular risk markers. Nevertheless, poor evidence of 
CVD risk factors, especially in youth has been described. 
Data obtained within the Healthy Lifestyle in  Europe by Nutrition in 
Adolescence Cross-Sectional Study (HELENA-CSS) study provide an excellent 
opportunity to study the association of UCP1, UCP2 and UCP3 SNPs with CVD risk 
factors in European adolescents. The HELENA study was designed  to  provide 
reliable data on nutrition and health-related variables in a relatively large sample of 
European adolescents from 9 different countries and includes information on 18 SNPs 
of UCP1, UCP2 and UCP3 genes as well as a number of CVD risk factors. To our 
knowledge, UCPs polymorphisms have not been identified in GWAS of body weight 
or body composition in adults or other age groups 
The aim of this study was therefore to examine the association of 18 UCP1, 
UCP2 and UCP3 SNPs (see Table 1) with CVD risk factors in European adolescents. 
Material and methods 
Participants 
The HELENA-CSS attempted to report the lifestyle and nutritional status of European 
adolescents. A total of 3865 participants (12-18 year old) of nine European countries 
(Greece, Germany, Belgium, France, Hungary, Italy, Sweden, Austria and  Spain) 
were selected to be part of this study. They were randomly selected from public and 
private schools in each city between October 2006 and December 2007. We collected 
blood samples of one-third of these participants (N=1155) with the  consequent 
genetic analysis and clinical biochemistry assays. Finally, 1057 (552  girls) 
adolescents with UCPs SNPs and CVD risk factors data were included in this study. 
Adolescents and corresponding parents/guardians were fully informed about aims and 
methods of the study such as inclusion criteria (24,25), and signed an informed 
written consent. Ethical guidelines of the Declaration of Helsinki 1964 (revision of 
Edinburgh 2000), Good Clinical Practice, and legislation about clinical research in 
humans in each of the participating countries were respected by the study. Human 
research committees of each center involved approved the protocol (26). 
Assessment of Cardiovascular Risk Factors 
A total of 30 ml of blood samples were drawn after a 10-h overnight fast at school 
between 0830 and 0900 hours following a standardized blood collection protocol. 
Serum/plasma was centrifuged directly at the schools at 3500 rpm (for 15 min, at 
room temperature). After centrifugation they were stored and transported (4-7ºC) to 
the central laboratory (Bonn, Germany) where they were deposited at -80ºC as 
explained in detailed elsewhere (27). Serum concentrations of cardiovascular risk 
factors were measured in centralized laboratories. 
The CVD risk factors analysed included serum total cholesterol, high-density 
lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL), ApoA1, ApoB, leptin, 
triglycerides and glucose, which were measured on the Dimension RxL clinical 
chemistry system (Dade Behring, Schwalbach, Germany) with enzymatic methods. 
Insulin was measured by a solid-phase two-site chemiluminescent immunometric 
assay with an Immulite 2000 analyzer (DPC Biermann GmbH, Bad Nauheim, 
Germany). Homeostasis model assessment (HOMA) was calculated ([glycaemia X 
insulin]/22.5) as resistance to insulin indicator, along with the Quantitative Insulin 
Sensitivity Check Index (QUICKI), which was calculated as 1/[log(insulin) + 
log(glycaemia)].Blood pressure was measured with an automatic oscillometric device 
(OMRON M6). Adolescents quietly sat for 5 min before the  measurements, 
conducted on the right arm in an extended position. Two measures of diastolic and 
systolic blood pressure (DBP and SBP, respectively) were taken 5 min apart, and the 
mean of both values (in mmHg) was used in analyses. 
We computed a CVD risk score with the mean of the standardize value 
[(value- mean)/standard deviation] of the following variables: Total cholesterol/HDL, 
triglycerides, HOMA, systolic blood pressure, and triceps and subscapular skinfolds 
(28). The characteristics of the study sample, including CVD risk factors, are shown 
in Table 2. 
Genotyping 
Blood for DNA extraction was collected in EDTA K3 tubes, stored at the Analytical 
Laboratory at the University of Bonn, and then sent to  the Genomic Analysis 
Laboratory at the Institut Pasteur de Lille (Lille, France). DNA was extracted from 
white blood cells with the Puregene kit (QIAGEN, Courtaboeuf, France) and stored at 
20°C. Samples were genotyped by an Illumina System (Illumina, Inc, San Diego, 
California) and the software used was GoldenGate (Inc, San Francisco, California). 
High rate of genotyping success was performed (≥97,8%) and each polymorphism 
respected the Hardy-Weinberg equilibrium (P>0.2 in all cases; Table 1). Several 
polymorphisms of the same genes showed linkage disequilibrium between them 
(Figures 1 and 2). 
Statistical analysis 
Deviations from Hardy-Weinberg equilibrium (HWE) were determined by means of 
an exact test and considering a p value of 0.05 as a threshold. Associations between 
genetic markers and CVD risk factors were assessed through linear models. Five 
inheritance models (dominant, recessive, log-additive, codominant and overdominant) 
were used for all analyses, except in those where rs2071416, rs2735572 and 
rs17132534 SNPs were involved. These polymorphisms were analysed using only a 
dominant model due to  the low number of minor homozygotes (minor allele 
frequency < 0.1; Table 1). Previous findings shown the association between non- 
additive models with UCPs, which indicates the interest of perform this five models 
and compare the additive models with non-additives ones (29). Adjustment variables 
were body mass index (calculated as weight in kilograms divided by height in meters 
squared), age, gender and center. For each SNP, P values were computed using the 
likelihood ratio test (LRT) between a model with the polymorphism and a null model 
without it. These analyses were performed with the “SNPassoc” R package (30). We 
considered the associations between all SNPs and each phenotype under a given 
heritage model such as the family test, i.e. the number of tests were equal to the 
number of SNPs analysed for a given phenotype. We selected the significant 
genotype-phenotype associations to perform haplotype analysis, i.e. only SNPs and 
phenotypes significant associated were considered for next analyses. Given the 
exploratory nature of these analyses and the reduced number of independent tests 
(markers are in  linkage disequilibrium), the Bonferroni correction could be too 
conservative (31). Instead of this method, we performed an exploratory selection of 
associations using an approach that controls the expected proportion of false positives 
(False Discovery Rate [FDR]) (32). Therefore, associations  with FDR <  0.1  were 
used in haplotype analyses. 
Linkage disequilibrium between polymorphisms and haplotype  block 
structures were evaluated with Haploview 4.2 
(http://www.broad.mit.edu/mpg/haploview) and the  R package  haplo.stats (33). First, 
haplotype blocks were generated by the algorithm of four-gamete rules (34) using 
Haploview. For each block, we tested if the observed frequencies of haplotypes were 
deviated    from    those    expected    under    linkage    equilibrium    using “haplo.em” 
{haplo.stats} (P = 0 in all blocks). Finally, we assessed the association between 
haplotypes and phenotypes by means of a permutation procedure performed with 
haplo.score {haplo.stats}. Only additive and dominant models were considered given 
the low frequency of some haplotypes. For those significant associations  we 
performed regressions between haplotypes and phenotypes with the purpose of testing 
significant differences between haplotype levels. These regressions were performed 
with haplo.glm {haplo.stats}. Again, the FDR was calculated from the P values for 
differences between the reference haplotype (the most frequent) and other haplotypes. 
Results 
Association between UCP polymorphisms and CVD Risk Factors 
Two UCP2 SNPs were individually associated with CVD risk factors after multiple- 
comparison corrections with a FDR<0.05 threshold. Associations with FDR<0.1 were 
also selected as a screening method to further haplotype analyses (Figure 3). All 
individual comparisons between genotypes and CVD risk factors are presented in 
supplementary file. We observed that the G minor allele of rs2735572 SNP and the T 
minor allele of rs17132534 SNP were associated with higher DBP under a dominant 
inheritance model (beta coefficient=0.04, P=0.001; FDR=0.009 and beta 
coefficient=0.04, P=8e−04; FDR=0.009 respectively; beta coefficients obtained from 
models with the response variable log transformed; Figure 3). 
Association between UCP polymorphism haplotypes and CVD risk factors 
UCP1 block contains the rs12502572, rs11932232, rs6822807, rs6818140, and 
rs2071416 SNPs (Figure 1). The AATAG haplotype of UCP1 was significantly 
associated with a higher ApoB/ApoA1 ratio than the reference GATAT haplotype 
(global P=0.046; difference between groups =0.06; 95CI = 0.02 - 0.10; P= 0.008; 
FDR = 0.031; under additive model; differences between groups obtained from 
models with the response variable  log transformed, respectively). The AATAG 
haplotype was also associated with higher ApoB levels than the reference GATAT 
haplotype (global P=0.045; difference between groups =0.06; 95CI = 0.02 - 0.10; P= 
0.008; FDR = 0.031; under additive model). Also an association between the UCP3 
block 2 (rs7930460, rs2075577 and rs2734828, Figure 2) and the risk score was 
observed. The ACC haplotype was associated with a higher risk score compared with 
the ATC haplotype (global P=0.008; difference between groups= 0.06; 95CI = 0.02 - 
0.10; P= 0.0036; FDR = 0.01; under dominant model). 
Discussion 
We observed that the UCP2 G and T alleles of the rs2735572 and rs17132534 SNPs 
were associated with higher diastolic blood pressure in European adolescents. 
Moreover, we found that the UCP1 AATAG haplotype was associated with higher 
serum ApoB/ApoA1 and ApoB levels. Finally, the UCP3 ACC haplotype was 
associated with a higher CVD risk score. Taken together, these findings suggest that 
UCPs may have an important role in cardiovascular health already in the first decades 
of life. 
To our knowledge, this is the first study investigating the association between 
UCPs and CVD risk factors in European adolescents. Several studies with smaller 
sample sizes (6,21,35,36) reported an association of single polymorphisms of UCP3 
SNPs or combined haplotypes of UCP2/UCP3 with several CVD risk factors such as 
TC and LDL levels,  insulin or HOMA in adults. In contrast, we observed no 
association of these UCPs SNPs with CVD risk factors in European adolescents. 
These discordances may be due to the fact that they are population dependent, with 
possibly different allele frequencies and penetrance in these populations. Also 
differences in age, inter-country differences in lifestyle behaviours and sample sizes 
are important and could lead to differences across studies. 
A plausible mechanism to partially explain the observed associations is that 
polymorphisms or haplotypes of UCPs could alter UCP functions and predispose to 
cardiovascular risk or an increased Risk Score (due to it is make up of cardiovascular 
risk factors). This dysfunction may explain the phenotypes observed with CVD risk 
through, i) dysfunction of the process of oxidation of fatty acids, leading to altered 
serum lipid levels as TC, LDL, HDL or TG (9,15), ii) in relation to ROS regulation 
mediated by UCP2; Pierelli et al. (37) showed that knockout mice deletion of the 
UCP2 gene contributes to atherosclerosis lesion development and a significantly 
shorter lifespan. Several studies in humans and cultured cells suggested that excessive 
ROS production is involved in the atherosclerotic plaque formation and progression 
(38,39). Therefore, evidence suggests that decreasing ROS production is a remarkable 
target to prevent the atherosclerotic process. UCP2 negatively regulates intracellular 
ROS production (12,13) making it a potential therapeutic target for the treatment of 
vascular diseases, iii) UCPs have been also  related to blood pressure control. 
Dhamrait et al. (40) described the role of UCPs in the regulation of angiotensin- 
converting enzyme (ACE). This enzyme plays a pivotal component of the endocrine 
renin–angiotensin system (RAS), also playing a key role in the regulation of the 
human circulation. ACE favours the rise of angiotensin II and aldosterone, leading to 
salt and water retention by the kidney and to constriction of small blood vessels in the 
arterial tree. Taken together, these actions serve to elevate blood pressure. Moreover, 
Dhamrait et al. (40) showed that some UCP3 and UCP2 SNPs were associated with 
higher age-adjusted ACE activity, which could contribute to a hypertension status, 
which is also consistent with our findings. Cardiovascular diseases are pathologie s 
with a long-term latency period and modifiable cardiovascular risks factors, which 
makes prevention fundamental, especially in these populations with genetic 
predisposition. 
A limitation of our study is its cross-sectional nature. Our results should be 
considered carefully and studies with larger sample size could help to further confirm 
this possible genetic predisposition. 
In conclusion, we observed an association between the UCP2 rs2735572 and 
rs17132534 SNPs with higher diastolic blood pressure in adolescents from nine 
European countries. We also observed a haplotype association of UCP1 and UCP3 
with higher blood apolipoproteins levels and risk score, respectively. These findings 
suggest that UCPs may have an important role in the development of CVD 
predisposition already in European adolescents. 
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Figure Legend 
• Figure 1. Haploview result belonging to blo ck 1 of UCP1 polymorphisms,
which contains (rs12502572, rs11932232, rs6822807, rs6818140 y
rs2071416), according to genotyping data of this study. Boxes number
referred to linkage disequilibrium (D’) between SNPs, boxes with no number
means 100% linkage (D’ = 1). Colour legend: i) Bright red = high D’; White =
low D’ (see Haploview documentation for further details;
http://www.broad.mit.edu/mpg/haploview).
• Figure 2. Blocks 1, 2 and 3 of UCP2 and UCP3 polymorphisms, which
contains rs2735572, rs660339, rs17132534 and rs659366 SNPs for block 1
(UCP2); rs7930460, rs2075577 and rs2734828 SNPs for block 2 (UCP3);
rs1800006 and rs1800849 SNPs for block 3 (UCP3), according to genotyping
data of this study. Boxes number referred to linkage disequilibrium (D’)
between SNPs, boxes with no number means 100% linkage (D’ = 1). Colour
legend: i) Bright red = high D’; White = low D’ (see  Haploview
documentation for further details; http://www.broad.mit.edu/mpg/haploview).
• Figure 3. Significant associations between phenotypes and UPC SNPs
(FDR<0.1). For each association, the phenotypes and markers implicated are
shown, along with the inheritance model, P value and FDR. Values  are
adjusted for body mass index, center, sex, and age.
• Figure 3 (continuation). Significant associations between phenotypes and
SNPs (FDR<0.1). For each association, the phenotypes and  markers
implicated are shown, along with the inheritance model, P value and FDR.
Values are adjusted for body mass index, center, sex, and age.

Table 1: Frequency of the major and minor alleles is shown, along with the 
corresponding frequency of genotypes. In addition, sample size and results of exact 







allele homozygous Heterozygous 
freq. 
Minor 
homozygous S ample pHWE 
Table 2: Mean ± SD of cardiovascular risk factors. 
freq. freq. freq. freq. size 
UCP1 
rs2071415 T C 0.85 0.15 0.73 0.25 0.03 1057 0.39 
rs7688743 G A 0.81 0.19 0.65 0.32 0.04 1057 0.92 
rs6818140 A G 0.81 0.19 0.65 0.32 0.03 1057 0.32 
rs6822807 T C 0.73 0.27 0.53 0.4 0.07 1056 0.59 
rs11932232 A G 0.81 0.19 0.65 0.32 0.03 1057 0.32 
rs12502572 G A 0.64 0.36 0.42 0.45 0.13 1057 0.74 
rs6536991 T C 0.73 0.27 0.53 0.4 0.07 1057 1 
rs2071416 T G 0.92 0.08 0.84 0.15 0.01 1057 0.31 
UCP2 
rs2735572 G A 0.94 0.06 0.88 0.12 0 1057 0.58 
rs17132534 T C 0.94 0.06 0.88 0.12 0 1057 0.79 
rs660339 C T 0.61 0.39 0.38 0.47 0.15 1034 0.65 
rs659366 C T 0.64 0.36 0.42 0.46 0.13 1057 0.84 
UCP3 
rs7930460 A G 0.79 0.21 0.62 0.33 0.05 1057 0.78 
rs2075577 T C 0.53 0.47 0.27 0.52 0.21 1057 0.22 
rs2734828 C T 0.75 0.25 0.56 0.37 0.06 1057 0.81 
rs3781907 T C 0.74 0.26 0.54 0.39 0.07 1057 0.75 
Phenotype All (n=1057) Male (n=505) Female 
(n=552) 
Age (years) 14.71 ± 1.22 14.74 ± 1.25 14.68 ± 1.2 
Weight (kg) 58.72 ± 12.67 61.86 ± 14.29 55.85 ± 10.17 
Height (cm) 165.46 ± 9.34 169.5 ± 9.91 161.76 ± 6.98 
BMI (kg / m2) 21.34 ± 3.67 21.39 ± 3.99 21.3 ± 3.37 
Cholesterol (mg/dL) 160.74 ± 27.69 154.03 ± 26.13 166.88 ± 27.68 
BMI: body mass index (calculated as weight in kilograms divided by height in meters 
squared) HDL: high density lipoprotein; LDL: low density lipoprotein; Apo: 
apolipoprotein; HOMA: homeostatic model assessment; QUICKI: quantitative insulin 
sensitivity check index; SBP: systolic blood pressure; DBP: diastolic blood pressure 
• 
HDL (mg/dL) 55.26 ± 10.67 53.17 ± 10.12 57.17 ± 10.81 
LDL (mg/dL) 94.49 ± 25.09 90.78 ± 24.32 97.89 ± 25.33 
Triglycerides (mg/dL) 69 ± 35.09 64.13 ± 31.65 73.46 ± 37.45 
LDL/HDL 1.78 ± 0.63 1.78 ± 0.65 1.78 ± 0.6 
Cholesterol/HDL 2.99 ± 0.66 2.98 ± 0.69 2.99 ± 0.63 
Triglycerides/HDL 1.33 ± 0.88 1.29 ± 0.83 1.37 ± 0.92 
ApoA1(mg/dL) 1.5 ± 0.22 1.46 ± 0.21 1.55 ± 0.23 
ApoB (mg/dL) 0.65 ± 0.16 0.63 ± 0.15 0.68 ± 0.16 
ApoB/ApoA1 0.44 ± 0.13 0.44 ± 0.13 0.45 ± 0.13 
apoB/LDL 0.27 ± 0.03 0.27 ± 0.03 0.27 ± 0.03 




10.31 ± 7.79 
2.35 ± 1.96 
10.16 ± 8.82 
2.36 ± 2.24 
10.46 ± 6.7 
2.34 ± 1.65 
QUICKI 0.35 ± 0.03 0.35 ± 0.03 0.35 ± 0.03 
SBP (mm Hg) 120.03 ± 13.3 124.16 ± 13.93 116.29 ± 11.5 
DBP (mm Hg) 68.03 ± 8.84 67.52 ± 8.91 68.49 ± 8.76 
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